Cartesian Therapeutics
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Cartesian Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 77% to $26,004,000. The net income dropped to -$219,710,000 and profit margin reached -845%. Total operating expenses were $110,867,000.

Profit Margin

Cartesian Therapeutics, Inc. (NASDAQ:RNAC): Profit margin
2014 3.04M -12.88M -423.68%
2015 6.01M -25.17M -418.8%
2017 207K -65.32M -31556.04%
2019 6.67M -55.35M -828.97%
2020 16.59M -68.87M -414.99%
2021 85.07M -25.68M -30.19%
2022 110.77M 35.37M 31.94%
2023 26.00M -219.71M -844.91%

RNAC Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2017 2015 2014
Revenue
Revenue
26.00M110.77M85.07M16.59M6.67M207K6.01M3.04M
Cost of revenue
1.55M2.03M000000
Gross profit
24.45M108.74M85.07M16.59M6.67M207K6.01M3.04M
Operating exp.
Research and development
71.83M72.37M68.73M54.50M42.74M45.16M22.98M10.48M
Selling and marketing
00000000
Total operating expenses
110.86M96.23M89.67M73.41M57.10M63.24M30.27M18.43M
Operating income
-86.41M14.53M-4.59M-56.82M-52.45M-63.78M-25.30M-15.39M
Other income (expenses), net
-152.29M23.26M-2.28M-12.05M-2.89M-1.53M130K2.51M
Income before tax
-238.71M34.77M-9.72M-68.87M-55.35M-65.32M-25.17M-12.88M
Income tax expense
-19M-609K15.96M1.64M0000
Net income
-219.71M35.37M-25.68M-68.87M-55.35M-65.32M-25.17M-12.88M
Earnings per share
Basic EPS
-42.497.33-6.74-20.42-36.46-95.94-40.5-38.17
Diluted EPS
-42.492.98-6.74-20.42-36.46-95.94-40.5-38.17